Clinical and electrocardiographic outcomes evaluated by telemedicine of outpatients with clinical suspicion of COVID-19 treated with chloroquine compounds in Brazil†

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

Ana Carolina D. Alves¹  David C. Peixoto²  Magda C. Pires³  Paulo R. Gomes⁴  Mayara S. Mendes⁴  Luìs Antônio B. Tonaco⁴  Leonardo B. Ribeiro⁴  Bruno R. Nascimento⁵  Gabriela M. M. Paixão⁵  Antonio Luiz P. Ribeiro⁵ 

[1]Curso de Medicina, Faculdade de Saúde e Ecologia Humana (FASEH), Belo Horizonte, MG, Brazil

[2]Departamento de Clínica Médica, Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

[3]Departamento de Estatística, Instituto de Ciências Exatas (ICEX) da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

[4]Serviço de Cardiologia e Cirurgia Cardiovascular e Centro de Telessaúde do Hospital das Clínicas da UFMG, Belo Horizonte, MG, Brazil

[5]Serviço de Cardiologia e Cirurgia Cardiovascular e Centro de Telessaúde do Hospital das Clínicas da UFMG, Belo Horizonte, MG, Brazil

[6]Departamento de Clínica Médica, Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

关键词: COVID-19;    chloroquine;    treatment;    outcomes;    prognosis;    electrocardiogram;    telemedicine;   

DOI  :  10.3389/fcvm.2023.1028398

 received in 2022-08-26, accepted in 2023-01-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

AimsTo evaluate clinical and electrocardiographic outcomes of patients with COVID-19, comparing those using chloroquine compounds (chloroquine) to individuals without specific treatment.MethodsOutpatients with suspected COVID-19 in Brazil who had at least one tele-electrocardiography (ECG) recorded in a telehealth system were enrolled in two arms (Group 1: chloroquine and Group 2: without specific treatment) and one registry (Group 3: other treatments). Outcomes were assessed through follow-up calls (phone contact, days 3 and 14) and linkage to national mortality and hospitalization databases. The primary outcome was composed of: hospitalization, intensive care admission, mechanical ventilation, and all-cause death, and the ECG outcome was the occurrence of major abnormalities by the Minnesota code. Significant variables in univariable logistic regression were included in 4 models: 1-unadjusted; 2-adjusted for age and sex; 3-model 2 + cardiovascular risk factors and 4-model 3 + COVID-19 symptoms.ResultsIn 303 days, 712 (10.2%) patients were allocated in group 1, 3,623 (52.1%) in group 2 and 2,622 (37.7%) in group 3; 1,969 had successful phone follow-up (G1: 260, G2: 871, and G3: 838). A late follow-up ECG was obtained for 917 (27.2%) patients [group 1: 81 (11.4%), group 2: 512 (14.1%), group 3: 334 (12.7%)]. In adjusted models, chloroquine was independently associated with greater chance of the composite clinical outcome: phone contact (model 4): OR = 3.24 (95% CI 2.31–4.54), p < 0.001. Chloroquine was also independently associated with higher mortality, assessed by phone + administrative data (model 3): OR = 1.67 (95% CI 1.20–2.28). However, chloroquine did not associate with the occurrence of major ECG abnormalities [model 3; OR = 0.80 (95% CI 0.63–1.02, p = 0.07)]. Abstracts with partial results of this work was accepted in the American Heart Association Scientific Sessions, November 2022, in Chicago, IL, USA.ConclusionChloroquine was associated with a higher risk of poor outcomes in patients suspected to have COVID-19 when compared to those who received standard care. Follow-up ECGs were obtained in only 13.2% of patients and did not show any significant differences in major abnormalities amongst the three groups. In the absence of early ECG changes, other side effects, late arrhythmias or deferral of care may be hypothesized to explain the worse outcomes.

【 授权许可】

Unknown   
Copyright © 2023 Nascimento, Paixão, Tonaco, Alves, Peixoto, Ribeiro, Mendes, Gomes, Pires and Ribeiro.